Do analysts prefer MBIO or NRSN?

NeuroSense Therapeutics has a consensus target price of $8.50, suggesting a potential upside of 2,016.53%. Given NeuroSense Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe NeuroSense Therapeutics is more favorable than Mustang Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mustang Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NeuroSense Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67

Which has higher valuation & earnings, MBIO or NRSN?

Mustang Bio is trading at a lower price-to-earnings ratio than NeuroSense Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mustang Bio N/A N/A -$1.92M -$0.45 N/A NeuroSense Therapeutics N/A N/A -$11.12M -$0.54 N/A

Is MBIO or NRSN more profitable?

NeuroSense Therapeutics' return on equity of 0.00% beat Mustang Bio's return on equity. Company Net Margins Return on Equity Return on Assets Mustang Bio N/A -34.23% -17.55% NeuroSense Therapeutics N/A N/A N/A

Is APLT or MBIO more profitable?

Mustang Bio's return on equity of -34.23% beat Applied Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Applied Therapeutics N/A -340.84% -175.00% Mustang Bio N/A -34.23% -17.55%

Do analysts recommend HIND or MBIO?

Vyome presently has a consensus price target of $9.25, suggesting a potential upside of 314.80%. Given Vyome's stronger consensus rating and higher possible upside, research analysts plainly believe Vyome is more favorable than Mustang Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vyome 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 Mustang Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is HIND or MBIO more profitable?

Mustang Bio has a net margin of 0.00% compared to Vyome's net margin of -3,024.84%. Mustang Bio's return on equity of -34.23% beat Vyome's return on equity. Company Net Margins Return on Equity Return on Assets Vyome -3,024.84% -197.33% -138.14% Mustang Bio N/A -34.23% -17.55%

Do analysts recommend MBIO or SYBX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mustang Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Synlogic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is MBIO or SYBX more profitable?

Synlogic's return on equity of -26.47% beat Mustang Bio's return on equity. Company Net Margins Return on Equity Return on Assets Mustang Bio N/A -34.23% -17.55% Synlogic N/A -26.47% -18.00%

Do analysts prefer MBIO or PASG?

Passage Bio has a consensus price target of $13.25, suggesting a potential upside of 178.95%. Given Passage Bio's stronger consensus rating and higher possible upside, analysts plainly believe Passage Bio is more favorable than Mustang Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mustang Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Passage Bio 1 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.11

Which has preferable earnings and valuation, MBIO or PASG?

Mustang Bio is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mustang Bio N/A N/A -$1.92M -$0.45 N/A Passage Bio N/A N/A -$45.52M -$11.32 N/A

Is MBIO or PASG more profitable?

Mustang Bio's return on equity of -34.23% beat Passage Bio's return on equity. Company Net Margins Return on Equity Return on Assets Mustang Bio N/A -34.23% -17.55% Passage Bio N/A -218.59% -72.93%

Mustang Bio (MBIO) Competitors

$0.56 +0.02 (+3.13%)

As of 09/3/2026 03:59 PM Eastern

Compare

MBIO vs. NRSN, APLT, HIND, SYBX, and PASG

Should you buy Mustang Bio stock or one of its competitors? Mustang Bio's main competitors and comparable companies include NeuroSense Therapeutics (NRSN), Applied Therapeutics (APLT), Vyome (HIND), Synlogic (SYBX), and Passage Bio (PASG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Mustang Bio compare to NeuroSense Therapeutics?

Mustang Bio (NASDAQ:MBIO) and NeuroSense Therapeutics (NASDAQ:NRSN) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, media sentiment, dividends, valuation, analyst recommendations and profitability.

Mustang Bio is trading at a lower price-to-earnings ratio than NeuroSense Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mustang Bio	N/A	N/A	-$1.92M	-$0.45	N/A
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$0.54	N/A

Mustang Bio has a beta of 2.05, indicating that its share price is 105% more volatile than the broader market. Comparatively, NeuroSense Therapeutics has a beta of 1.6, indicating that its share price is 60% more volatile than the broader market.

NeuroSense Therapeutics' return on equity of 0.00% beat Mustang Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mustang Bio	N/A	-34.23%	-17.55%
NeuroSense Therapeutics	N/A	N/A	N/A

In the previous week, NeuroSense Therapeutics had 4 more articles in the media than Mustang Bio. MarketBeat recorded 4 mentions for NeuroSense Therapeutics and 0 mentions for Mustang Bio. NeuroSense Therapeutics' average media sentiment score of 0.25 beat Mustang Bio's score of 0.00 indicating that NeuroSense Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Mustang Bio	Neutral
NeuroSense Therapeutics	Neutral

NeuroSense Therapeutics has a consensus target price of $8.50, suggesting a potential upside of 2,016.53%. Given NeuroSense Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe NeuroSense Therapeutics is more favorable than Mustang Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mustang Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

10.0% of Mustang Bio shares are held by institutional investors. Comparatively, 1.0% of NeuroSense Therapeutics shares are held by institutional investors. 4.0% of Mustang Bio shares are held by insiders. Comparatively, 27.4% of NeuroSense Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

NeuroSense Therapeutics beats Mustang Bio on 10 of the 14 factors compared between the two stocks.

How does Mustang Bio compare to Applied Therapeutics?

Applied Therapeutics (NASDAQ:APLT) and Mustang Bio (NASDAQ:MBIO) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk and earnings.

Mustang Bio's return on equity of -34.23% beat Applied Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Applied Therapeutics	N/A	-340.84%	-175.00%
Mustang Bio	N/A	-34.23%	-17.55%

98.3% of Applied Therapeutics shares are held by institutional investors. Comparatively, 10.0% of Mustang Bio shares are held by institutional investors. 1.6% of Applied Therapeutics shares are held by company insiders. Comparatively, 4.0% of Mustang Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Applied Therapeutics' average media sentiment score of 0.00 equaled Mustang Bio'saverage media sentiment score.

Company	Overall Sentiment
Applied Therapeutics	Neutral
Mustang Bio	Neutral

Mustang Bio has lower revenue, but higher earnings than Applied Therapeutics. Mustang Bio is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A
Mustang Bio	N/A	N/A	-$1.92M	-$0.45	N/A

Applied Therapeutics currently has a consensus target price of $1.00, suggesting a potential upside of 870.87%. Given Applied Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Applied Therapeutics is more favorable than Mustang Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Mustang Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Applied Therapeutics has a beta of 2.08, suggesting that its stock price is 108% more volatile than the broader market. Comparatively, Mustang Bio has a beta of 2.05, suggesting that its stock price is 105% more volatile than the broader market.

Summary

Applied Therapeutics beats Mustang Bio on 7 of the 11 factors compared between the two stocks.

How does Mustang Bio compare to Vyome?

Vyome (NASDAQ:HIND) and Mustang Bio (NASDAQ:MBIO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.

Vyome presently has a consensus price target of $9.25, suggesting a potential upside of 314.80%. Given Vyome's stronger consensus rating and higher possible upside, research analysts plainly believe Vyome is more favorable than Mustang Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vyome	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Mustang Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Mustang Bio has a net margin of 0.00% compared to Vyome's net margin of -3,024.84%. Mustang Bio's return on equity of -34.23% beat Vyome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vyome	-3,024.84%	-197.33%	-138.14%
Mustang Bio	N/A	-34.23%	-17.55%

In the previous week, Vyome had 1 more articles in the media than Mustang Bio. MarketBeat recorded 1 mentions for Vyome and 0 mentions for Mustang Bio. Vyome's average media sentiment score of 0.00 equaled Mustang Bio'saverage media sentiment score.

Company	Overall Sentiment
Vyome	Neutral
Mustang Bio	Neutral

22.1% of Vyome shares are held by institutional investors. Comparatively, 10.0% of Mustang Bio shares are held by institutional investors. 33.0% of Vyome shares are held by insiders. Comparatively, 4.0% of Mustang Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Mustang Bio has lower revenue, but higher earnings than Vyome. Mustang Bio is trading at a lower price-to-earnings ratio than Vyome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vyome	$320K	48.92	-$10.26M	-$3.37	N/A
Mustang Bio	N/A	N/A	-$1.92M	-$0.45	N/A

Vyome has a beta of 1.5, suggesting that its share price is 50% more volatile than the broader market. Comparatively, Mustang Bio has a beta of 2.05, suggesting that its share price is 105% more volatile than the broader market.

Summary

Vyome beats Mustang Bio on 8 of the 14 factors compared between the two stocks.

How does Mustang Bio compare to Synlogic?

Mustang Bio (NASDAQ:MBIO) and Synlogic (NASDAQ:SYBX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.

Mustang Bio has a beta of 2.05, suggesting that its share price is 105% more volatile than the broader market. Comparatively, Synlogic has a beta of 0.48, suggesting that its share price is 52% less volatile than the broader market.

10.0% of Mustang Bio shares are held by institutional investors. Comparatively, 63.4% of Synlogic shares are held by institutional investors. 4.0% of Mustang Bio shares are held by company insiders. Comparatively, 2.6% of Synlogic shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Mustang Bio has higher earnings, but lower revenue than Synlogic. Synlogic is trading at a lower price-to-earnings ratio than Mustang Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mustang Bio	N/A	N/A	-$1.92M	-$0.45	N/A
Synlogic	$8K	1,867.97	-$23.36M	-$0.06	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mustang Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Synlogic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Synlogic's return on equity of -26.47% beat Mustang Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mustang Bio	N/A	-34.23%	-17.55%
Synlogic	N/A	-26.47%	-18.00%

In the previous week, Synlogic had 1 more articles in the media than Mustang Bio. MarketBeat recorded 1 mentions for Synlogic and 0 mentions for Mustang Bio. Mustang Bio's average media sentiment score of 0.00 equaled Synlogic'saverage media sentiment score.

Company	Overall Sentiment
Mustang Bio	Neutral
Synlogic	Neutral

Summary

Mustang Bio and Synlogic tied by winning 5 of the 10 factors compared between the two stocks.

How does Mustang Bio compare to Passage Bio?

Mustang Bio (NASDAQ:MBIO) and Passage Bio (NASDAQ:PASG) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends and profitability.

Mustang Bio has a beta of 2.05, suggesting that its share price is 105% more volatile than the broader market. Comparatively, Passage Bio has a beta of 1.43, suggesting that its share price is 43% more volatile than the broader market.

Passage Bio has a consensus price target of $13.25, suggesting a potential upside of 178.95%. Given Passage Bio's stronger consensus rating and higher possible upside, analysts plainly believe Passage Bio is more favorable than Mustang Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mustang Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Passage Bio	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11

Mustang Bio is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mustang Bio	N/A	N/A	-$1.92M	-$0.45	N/A
Passage Bio	N/A	N/A	-$45.52M	-$11.32	N/A

10.0% of Mustang Bio shares are owned by institutional investors. Comparatively, 53.5% of Passage Bio shares are owned by institutional investors. 4.0% of Mustang Bio shares are owned by company insiders. Comparatively, 4.9% of Passage Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Passage Bio had 2 more articles in the media than Mustang Bio. MarketBeat recorded 2 mentions for Passage Bio and 0 mentions for Mustang Bio. Mustang Bio's average media sentiment score of 0.00 equaled Passage Bio'saverage media sentiment score.

Company	Overall Sentiment
Mustang Bio	Neutral
Passage Bio	Neutral

Mustang Bio's return on equity of -34.23% beat Passage Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mustang Bio	N/A	-34.23%	-17.55%
Passage Bio	N/A	-218.59%	-72.93%

Summary

Passage Bio beats Mustang Bio on 7 of the 12 factors compared between the two stocks.

Get Mustang Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MBIO vs. The Competition

Export

Metric	Mustang Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.11M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-1.24	12.66	273.29	25.38
Price / Sales	N/A	1,309.08	613.45	92.55
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	0.56	16.29	12.89	6.14
Net Income	-$1.92M	-$22.72M	$3.47B	$349.01M
7 Day Performance	4.17%	0.34%	0.60%	-0.27%
1 Month Performance	-5.72%	8.52%	5.73%	0.68%
1 Year Performance	-61.90%	52.66%	25.35%	14.84%

Mustang Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MBIO Mustang Bio	0.4716 of 5 stars	$0.56 +3.1%	N/A	-63.6%	$4.11M	N/A	N/A	100
NRSN NeuroSense Therapeutics	4.0569 of 5 stars	$0.42 -1.5%	$8.50 +1,923.3%	-62.5%	$16.11M	N/A	N/A	10	News Coverage Analyst Forecast
APLT Applied Therapeutics	1.4883 of 5 stars	$0.10 flat	$1.00 +870.9%	N/A	$15.86M	$1M	N/A	30
HIND Vyome	2.3717 of 5 stars	$2.17 +0.5%	$15.00 +591.2%	N/A	$15.16M	$320K	N/A	50	Analyst Forecast
SYBX Synlogic	0.0739 of 5 stars	$1.22 flat	N/A	-18.1%	$14.94M	$8K	N/A	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MBIO) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mustang Bio (MBIO) Competitors

MBIO vs. NRSN, APLT, HIND, SYBX, and PASG

How does Mustang Bio compare to NeuroSense Therapeutics?

Summary

How does Mustang Bio compare to Applied Therapeutics?

Summary

How does Mustang Bio compare to Vyome?

Summary

How does Mustang Bio compare to Synlogic?

Summary

How does Mustang Bio compare to Passage Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBIO vs. The Competition

Mustang Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mustang Bio (MBIO) Competitors

MBIO vs. NRSN, APLT, HIND, SYBX, and PASG

How does Mustang Bio compare to NeuroSense Therapeutics?

Which has higher valuation & earnings, MBIO or NRSN?

Which has more volatility & risk, MBIO or NRSN?

Is MBIO or NRSN more profitable?

Does the media favor MBIO or NRSN?

Do analysts prefer MBIO or NRSN?

Do insiders and institutionals have more ownership in MBIO or NRSN?

Summary

How does Mustang Bio compare to Applied Therapeutics?

Is APLT or MBIO more profitable?

Do insiders & institutionals have more ownership in APLT or MBIO?

Does the media favor APLT or MBIO?

Which has higher earnings & valuation, APLT or MBIO?

Do analysts rate APLT or MBIO?

Which has more risk & volatility, APLT or MBIO?

Summary

How does Mustang Bio compare to Vyome?

Do analysts recommend HIND or MBIO?

Is HIND or MBIO more profitable?

Does the media favor HIND or MBIO?

Do institutionals and insiders have more ownership in HIND or MBIO?

Which has stronger valuation & earnings, HIND or MBIO?

Which has more risk and volatility, HIND or MBIO?

Summary

How does Mustang Bio compare to Synlogic?

Which has more volatility and risk, MBIO or SYBX?

Do institutionals & insiders have more ownership in MBIO or SYBX?

Which has better earnings and valuation, MBIO or SYBX?

Do analysts recommend MBIO or SYBX?

Is MBIO or SYBX more profitable?

Does the media favor MBIO or SYBX?

Summary

How does Mustang Bio compare to Passage Bio?

Which has more risk and volatility, MBIO or PASG?

Do analysts prefer MBIO or PASG?

Which has preferable earnings and valuation, MBIO or PASG?

Do insiders & institutionals hold more shares of MBIO or PASG?

Does the media refer more to MBIO or PASG?

Is MBIO or PASG more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBIO vs. The Competition

Mustang Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools